Last reviewed · How we verify

Rickets — Treatment Landscape & Competitive Intelligence

Rickets (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Rickets, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Infuvite Adult Colecalciferol Novartis Vitamin D Vitamin D3 receptor 2000-01-01
Drisdol ERGOCALCIFEROL Esjay Pharma Provitamin D2 Compound [EPC] 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial 1941-01-01
Hornel FALECALCITRIOL Taisho Pharmaceutical
Calciferol Calciferol Department of Medical Services Ministry of Public Health of Thailand Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Rickets
  2. Department of Medical Services Ministry of Public Health of Thailand · 1 drug in Rickets
  3. Esjay Pharma · 1 drug in Rickets
  4. Novartis · 1 drug in Rickets
  5. Taisho Pharmaceutical · 1 drug in Rickets

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Rickets:

Cite this brief

Drug Landscape (2026). Rickets — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/rickets. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing